ganglion cell death
Recently Published Documents


TOTAL DOCUMENTS

263
(FIVE YEARS 40)

H-INDEX

51
(FIVE YEARS 5)

2022 ◽  
Vol 100 (S267) ◽  
Author(s):  
Rupali Vohra ◽  
Anna Luna Mølgaard Tams ◽  
Berta Sanz Morello ◽  
Zaynab Ahmad Mouhammad ◽  
Jens Hannibal ◽  
...  

Biology ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 763
Author(s):  
Andrés Fernández-Vega Cueto ◽  
Lydia Álvarez ◽  
Montserrat García ◽  
Ana Álvarez-Barrios ◽  
Enol Artime ◽  
...  

Glaucoma is an insidious group of eye diseases causing degeneration of the optic nerve, progressive loss of vision, and irreversible blindness. The number of people affected by glaucoma is estimated at 80 million in 2021, with 3.5% prevalence in people aged 40–80. The main biomarker and risk factor for the onset and progression of glaucoma is the elevation of intraocular pressure. However, when glaucoma is diagnosed, the level of retinal ganglion cell death usually amounts to 30–40%; hence, the urgent need for its early diagnosis. Molecular biomarkers of glaucoma, from proteins to metabolites, may be helpful as indicators of pathogenic processes observed during the disease’s onset. The discovery of human glaucoma biomarkers is hampered by major limitations, including whether medications are influencing the expression of molecules in bodily fluids, or whether tests to validate glaucoma biomarker candidates should include human subjects with different types and stages of the disease, as well as patients with other ocular and neurodegenerative diseases. Moreover, the proper selection of the biofluid or tissue, as well as the analytical platform, should be mandatory. In this review, we have summarized current knowledge concerning proteomics- and metabolomics-based glaucoma biomarkers, with specificity to human eye tissue and fluid, as well the analytical approach and the main results obtained. The complex data published to date, which include at least 458 different molecules altered in human glaucoma, merit a new, integrative approach allowing for future diagnostic tests based on the absolute quantification of local and/or systemic biomarkers of glaucoma.


2021 ◽  
Vol 162 (22) ◽  
pp. 851-860
Author(s):  
András Végh ◽  
Dániel Péter Magda ◽  
Ferenc Kilin ◽  
Anita Csorba ◽  
Mikós Resch ◽  
...  

Összefoglaló. A látószerv különböző betegségei, valamint egyes szisztémás megbetegedések részben vagy kifejezetten az ideghártya károsodásával járnak. A patológia segítségével ma már tudjuk, hogy ezek a betegségek a retina mely rétegének vagy rétegeinek elváltozásait okozzák: míg az időskori maculadegeneratio a külső retinában található fotoreceptorokat érinti kifejezetten a fovea centralis területén, addig a glaucoma a belső retina ganglionsejtjeinek pusztulásával, valamint e sejtek opticusrostjainak károsodásával jár a stratum ganglionaréban és a stratum neurofibrarumban. Az emberi retina sejtjei azonban egyelőre nem maradéktalanul karakterizáltak, az egyes sejttípusok számát csak becsülni tudjuk, így nem írhatók le az egyes sejtszintű elváltozások sem kellő pontossággal. A szövettani feldolgozás és vizsgálat megfelelő részletességgel tájékoztat a diagnózisról és az elváltozás súlyosságáról, értelemszerűen azonban ez a módszer in vivo nem használható a mindennapi klinikai gyakorlatban. A sejtszintű elváltozások ismerete az egyes kórképekben felvetette és szükségessé tette olyan in vivo, a klinikumban is alkalmazható vizsgálómódszerek kifejlesztését, amelyek lehetőséget nyújtanak a retina neurális és egyéb sejtjeinek celluláris és szubcelluláris szintű vizsgálatára, ideértve a vér alakos elemeit is, amelyek egészséges vagy neovascularis eredetű erekben áramlanak. A jelenleg is használt klinikai vizsgálatok mellett ezek a képalkotó módszerek segítségül szolgálhatnak a diagnózis megerősítésében vagy elvetésében, emellett az elváltozás súlyosságának megítélésében, valamint a progresszió vagy remisszió monitorozásában. Orv Hetil. 2021; 162(22): 851–860. Summary. Diseases of the visual system as well as many systemic illnesses are usually associated with retinal damage. With the help of pathology, we can clearly identify the affected layer(s): while age-related macular degeneration mostly damages the photoreceptors in the outer retina at the central fovea, glaucoma promotes ganglion cell death in the ganglion cell layer and damages respective neural fibers. However, the diverse cell types of the human retina have not been fully characterized yet, thus in most cases our knowledge on cellular pathologies is not precise enough. While histopathological preparation and examination of the retinal tissue provide more detailed information about the diagnosis and the severity of the condition, unfortunately, it cannot be used in vivo in everyday clinical practice. Our understanding of the cellular changes in different diseases has revealed a need for new everyday clinical examination methods that can be used in vivo to asses cellular and subcellular changes in neural and other cells of the retina, such as blood cells flowing in healthy vessels or in vessels of neovascular origin. In addition to the currently used clinical examination methods, these imaging methods could help confirm or dismiss diagnoses, assess the severity of a condition, and monitor disease progression or remission. Orv Hetil. 2021; 162(22): 851–860.


2021 ◽  
Vol 18 (5) ◽  
pp. 985-993
Author(s):  
Ying Li ◽  
Leilei Qin ◽  
Liang Ying ◽  
Hanguang Dong ◽  
Dabo Wang

Purpose: To investigate the protective effect of rutin against glaucoma in a rat model, and the mechanisms involved. Methods: Sprague-Dawley rats were injected hypertonic saline in the limbal vein for elevation of intraocular pressure (IOP). Rats in the treatment group were administered rutin at doses of 12.5, 25 or 50 mg/kg orally and daily for 21 days. Results: Rutin markedly (p < 0.05) reduced IOP and prevented loss of retinal ganglion cells (RGCs). The expression of apoptotic pathway proteins, i.e., Bcl-xL, Bcl-2, Bad and Bax were significantly (p < 0.05) regulated by rutin. Moreover, rutin caused a substantial decrease in TGF-β2 expression, and also down-regulated p-Smad2 and p-Smad3 dose-dependently (p < 0.05). Raised levels of collagen I, fibronectin and elastin were effectively down-regulated. Rutin substantially up-regulated the Akt pathway involved in cell survival, and markedly improved the survival of RGCs subjected to hypoxia in vitro (p < 0.05). Conclusion: These results reveal that rutin exerts protective effect against glaucoma in a rat model via a mechanism involving regulation of the TGF-β2/Smad2/3Akt/PTEN signaling pathways. Thus, rutin has potentials for use in the management of glaucoma.


Author(s):  
Yang Deng ◽  
Yunzhao Fu ◽  
Longxiang Sheng ◽  
Yixin Hu ◽  
Lishi Su ◽  
...  

Retinal ischemia is a common pathological event that can result in retinal ganglion cell (RGC) death and irreversible vision loss. The pathogenic mechanisms linking retinal ischemia to RGC loss and visual deficits are uncertain, which has greatly hampered the development of effective treatments. It is increasingly recognized that pyroptosis of microglia contributes to the indirect inflammatory death of RGCs. In this study, we report a regulatory NOD-like receptor, NOD-, LRR- and CARD-containing 5 (NLRC5), as a key regulator on microglial pyroptosis and the retinal ischemia process. Through an in-depth analysis of our recently published transcriptome data, we found that NLRC5 was significantly up-regulated in retina during ischemia–reperfusion injury, which were further confirmed by subsequent detection of mRNA and protein level. We further found that NLRC5 was upregulated in retinal microglia during ischemia, while NLRC5 knockdown significantly ameliorated retinal ischemic damage and RGC death. Mechanistically, we revealed that knockdown of NLRC5 markedly suppressed gasdermin D (GSDMD) cleavage and activation of interleukin-1β (IL-1β) and caspase-3, indicating that NLRC5 promotes both microglial pyroptosis and apoptosis. Notably, we found that NLRC5 directly bound to NLRP3 and NLRC4 in inflammasomes to cooperatively drive microglial pyroptosis and apoptosis mediating retinal ischemic damage. Overall, these findings reveal a previously unidentified key contribution of NLRC5 signaling to microglial pyroptosis under ischemia or hypoxia conditions. This NLRC5-dependent pathway may be a novel therapeutic target for treatment of ischemic retinopathy.


2021 ◽  
pp. 108623
Author(s):  
Natsuko Nakamura ◽  
Megumi Honjo ◽  
Reiko Yamagishi ◽  
Makoto Kurano ◽  
Yutaka Yatomi ◽  
...  

2021 ◽  
Vol 152 ◽  
pp. 105277
Author(s):  
Jennifer Ngolab ◽  
Saranya Canchi ◽  
Suhail Rasool ◽  
Abderrahman Elmaarouf ◽  
Kimberly Thomas ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Teresa Rolle ◽  
Antonio Ponzetto ◽  
Lorenza Malinverni

Glaucoma is a multifactorial optic neuropathy characterized by the continuous loss of retinal ganglion cells, leading to progressive and irreversible visual impairment. In this minireview, we report the results of the most recent experimental studies concerning cells, molecular mechanisms, genes, and microbiome involved in neuroinflammation processes correlated to glaucoma neurodegeneration. The identification of cellular mechanisms and molecular pathways related to retinal ganglion cell death is the first step toward the discovery of new therapeutic strategies. Recent experimental studies identified the following possible targets: adenosine A2A receptor, sterile alpha and TIR motif containing 1 (neurofilament light chain), toll-like receptors (TLRs) 2 and 4, phosphodiesterase type 4 (PDE4), and FasL-Fas signaling (in particular ONL1204, a small peptide antagonist of Fas receptors), and therapies directed against them. The continuous progress in knowledge provides interesting data, although the total lack of human studies remains an important limitation. Further research is required to better define the role of neuroinflammation in the neurodegeneration processes that occur in glaucomatous disease and to discover neuroprotective treatments amenable to clinical trials. The hereinafter reviewed studies are reported and evaluated according to their translational relevance.


Sign in / Sign up

Export Citation Format

Share Document